Media and News

PharmaNova to Present at Annual American Association of Pharmaceutical Scientists (AAPS) at 2010 FIP Pharmaceutical Sciences World Congress, New Orleans LA, November 14-18, 2010

PharmaNova to Present at Annual American Association of Pharmaceutical Scientists (AAPS) at 2010 FIP Pharmaceutical Sciences World Congress, New Orleans LA, November 14-18, 2010

PharmaNova Inc. announced that its Vice President Pharmaceutical Development, Dr. Deepak Thassu, will be speaking at the Annual American Association of Pharmaceutical Scientists (AAPS) at 2010 FIP Pharmaceutical Sciences World Congress in association with AAPS annual meeting and exposition to be held in November 14-18, 2010 in New Orleans, LA. 

Dr. Thassu has been invited to speak on fundamentals of Drug Delivery applying Nanotechnology at the AAPS Sunrise Sessions, Wednesday November 17 at 7:00am. The speech will also focused breakthrough innovations related to PharmaNova’s nanoparticle technology, known as NovaSperse℠, from PharmaNova Inc. of Victor, New York.   Dr. Thassu is an inventor of multiple US and EU drug delivery technology/formulation patents and is the author and/or editor of several books and book chapters.   In addition, Dr. Thassu has held senior scientific positions, both U.S. and international, with global pharmaceutical and biotechnology companies where he led several product development projects from concept to clinic.

About PharmaNova

PharmaNova Inc. is a privately held pharmaceutical company.  Our product candidates are derived from the re‐positioning and enhancement of known drugs using our proprietary NovaSperse℠ nanoparticle technology platform. We address low risk, fast to market products in areas of clear medical need and generate revenue from partnering and licensing strategies with commercialization partners and clients worldwide. PharmaNova also conducts contractual formulation development work applying NovaSperse technology to client‐owned products and compounds to support new product development or the extended life cycle management of existing products.  PharmaNova has other new product candidates in various stages in its development pipeline.   Our focus is on the development of novel, improved nanoparticle formulations of ophthalmic and anti-infective products.

« Back to Media

Member of the media wishing to learn more about Pharmanova should contact:
Rafael Larramendi, President | ral@rochester.rr.com | (585) 919 -9649.